Neovascularization induced around an artificial device implanted in the abdomen by the use of gelatinized fibroblast growth factor 2.
The development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes. We have been proceeding with the development of a bag-type BAP that can be easily implanted and that allows for the optional injection or rejection of cells at any time. If fibrosis develops around a BAP device, then the permeability of substances transmitted through a semipermeable membrane will decrease, thereby reducing the reactivity with glucose, so it is necessary for the material of the device to have an excellent histocompatibility. Furthermore, in order to improve the efficacy of BAP treatment, it is important to maintain an environment of ample blood flow around the device. We have created a bag-type device for BAP that is 20 x 20 mm in size and comprises two layers of membranes. We have used an EVAL membrane for the outer membrane of the two layers. The EVAL membrane is a semipermeable membrane with good insulin permeability, which functions as an immunoisolation membrane. The inner membrane consists of PAU-coated HD-PE (nonwoven material processed with polyaminourethan) and it is designed to function as a scaffold for cells. We used Lewis rats to determine whether the effectiveness of fibroblast growth factor 2 (bFGF) can be improved by concomitantly using bFGF with a capacity for blood vessel regeneration as well as bFGF immersed in a sheet of gelatin. We placed the BAP in the abdominal cavity and covered it with the greater omentum. We were able to significantly increase the blood flow and the number of new blood vessels in the tissue surrounding the BAP device by using gelatinized bFGF. There were only a few instances of fibrosis as a biological reaction to the EVAL membrane, and the infiltration of inflammatory cells was mild. There were no adverse effects related to implantation of the device. We confirmed in this study that the use of an implantable BAP device and bFGF allowed for a better blood flow around the BAP device. There were only minor instances of fibrosis and inflammation reaction around the BAP, thus indicating the BAP that we are currently developing to have an excellent histocompatibility.
Yuasa
Takeshi
T
Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan.
Rivas-Carrillo
Jorge D
JD
Navarro-Alvarez
Nalú
N
Soto-Gutierrez
Alejandro
A
Kubota
Yasuhiro
Y
Tabata
Yasuhiko
Y
Okitsu
Teru
T
Noguchi
Hirofumi
H
Matsumoto
Shinichi
S
Nakaji
Shuhei
S
Tanaka
Noriaki
N
Kobayashi
Naoya
N
D000005:Abdomen / Q000098:blood supply* / Q000473:pathology; D000818:Animals; D001808:Blood Vessels / Q000473:pathology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005780:Gelatin / Q000737:chemistry* / Q000494:pharmacology; D008422:Materials Testing; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D019397:Pancreas, Artificial; D051381:Rats; D011917:Rats, Inbred Lew
D016222:Fibroblast Growth Factor 2; D005780:Gelatin